Major trial proposes how to reduce ICU infections caused by staphylococcus aureus

pharmafile | October 18, 2021 | News story | Sales and Marketing  

A major US hospital-based clinical trial has highlighted the benefit of using nasal decolonisation to reduce ICU infections caused by staphylococcus aureus (S. aureus).

Clinical stage biotechnology company, Destiny Pharma, reports that the Phase IIII study explored the link between S. aureus decolonisation and ICU infection rates. S. aureus is an infection-causing pathogen, and is the primary bacterial pathogen causing ICU infections in the USA. According to the US Centers for Disease Control and Prevention, about one third of people carry this bacterium in their nose.

The Phase III study was the largest ever of this type, with over 300,000 patients in 233 US ICU. The trial compared levels of infection after the use of the current leading treatment, a nasal decolonisation antibiotic ointment, mupirocin, against a nasal antiseptic, iodophor.

Overall, the nasal antibiotic was shown to be superior for the reduction of S. aureus clinical cultures, compared to the nasal antiseptic iodophor.

The study has positive implications for Destiny Pharma’s novel XF-73 nasal gel, which is being developed as a nasal S. aureus decolonisation medicine. The issue of mupirocin resistance is a global concern, and products which are as effective but do not cause Antimicrobial Resistance (AMR) are urgently needed.

Neil Clark, Chief Executive Officer of Destiny Pharma, said: “This large, multi-year study clearly supports the value of nasal treatment to remove S. aureus and shows yet again the significant interest in improving the efficacy of nasal decolonisation because it is a major contributor to delivering a reduction in post-surgical S. aureus infections.”

Destiny Pharma’s XF-73 nasal gel is focused on delivering a novel decolonisation treatment and following the excellent phase 2 clinical data, reported earlier in 2021, we remain committed to finalising our phase 3 plans and bringing XF-73 to the hospital market to meet this clear and substantial clinical need.

“The company believes strongly that XF-73 has the potential to provide a major step change and improvement in S. aureus decolonisation compared to mupirocin – XF-73 is faster-acting with a broader antimicrobial action.”

Lina Adams

Related Content

No items found

Latest content